Related references
Note: Only part of the references are listed.Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor
Longying Jiang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum
Naoki Teno et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
A New FXR Ligand Chemotype with Agonist/Antagonist Switch
Moritz Helmstaedter et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Andrographolide: Chemical modification and its effect on biological activities
Gulshan Kumar et al.
BIOORGANIC CHEMISTRY (2020)
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Marcos Pedrosa et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Donatella Chianelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
Stefano Fiorucci et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Structural basis of GPBAR activation and bile acid recognition
Fan Yang et al.
NATURE (2020)
Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
Chao Li et al.
FRONTIERS IN PHARMACOLOGY (2020)
Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene
Shan Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Computational study of the binding mechanism between farnesoid X receptor α and antagonist N-benzyl-N-(3-(tertbutyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide
Juan Du et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2019)
FXR Regulates Intestinal Cancer Stem Cell Proliferation
Ting Fu et al.
CELL (2019)
Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis
Caroline Ovadia et al.
HEPATOLOGY (2019)
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation
Adriana Carino et al.
NUTRIENTS (2019)
Molecular tuning of farnesoid X receptor partial agonism
Daniel Merk et al.
NATURE COMMUNICATIONS (2019)
Capsaicin Improves Glucose Tolerance and Insulin Sensitivity Through Modulation of the Gut Microbiota-Bile Acid-FXR Axis in Type 2 Diabetic db/db Mice
Suocheng Hui et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2019)
Protein Expression Profiling Identifies Key Proteins and Pathways Involved in Growth Inhibitory Effects Exerted by Guggulsterone in Human Colorectal Cancer Cells
Rari Leo et al.
CANCERS (2019)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Michael Trauner et al.
HEPATOLOGY (2019)
Guggulsterone, a farnesoid X receptor antagonist lowers plasma trimethylamine-N-oxide levels: An evidence from in vitro and in vivo studies
A. Gautam et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists
Carmen Festa et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection
Yi Cao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2019)
Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool
Daniela Passeri et al.
MEDCHEMCOMM (2019)
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Xiaoxin X. Wang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
O. Erice et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists
Jurema Schmidt et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kris V. Kowdley et al.
HEPATOLOGY (2018)
Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR
Weili Zheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver
Guozhen Cui et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Bile acids in glucose metabolism in health and disease
Hagit Shapiro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects
A. Ahmad et al.
JOURNAL OF HEPATOLOGY (2018)
HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1α promoter
Xin Xu et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
Yanyan Diao et al.
FRONTIERS IN CHEMISTRY (2018)
The nuclear receptor superfamily: A structural perspective
Emily R. Weikum et al.
PROTEIN SCIENCE (2018)
Ligand binding and heterodimerization with retinoid X receptor alpha (RXR alpha) induce farnesoid X receptor (FXR) conformational changes affecting coactivator binding
Na Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases
Huey-Ling Chen et al.
JOURNAL OF BIOMEDICAL SCIENCE (2018)
Molecular Magnetic Resonance Imaging Accurately Measures the Antifibrotic Effect of EDP-305 a Novel Farnesoid X Receptor Agonist
Derek J. Erstad et al.
HEPATOLOGY COMMUNICATIONS (2018)
Steroidal or non-steroidal FXR agonists - Is that the question?
Len Verbeke et al.
JOURNAL OF HEPATOLOGY (2017)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system
A. Dash et al.
TOXICOLOGY IN VITRO (2017)
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
Adriana Carino et al.
SCIENTIFIC REPORTS (2017)
The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
Yasmeen M. Attia et al.
SCIENTIFIC REPORTS (2017)
A Novel Class of Natural FXR Modulators with a Unique Mode of Selective Co-regulator Assembly
Weili Zheng et al.
CHEMBIOCHEM (2017)
Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations
Zaki A. Sherif et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Obeticholic Acid: First Global Approval
A. Markham et al.
DRUGS (2016)
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid
Noortje Ijssennagger et al.
JOURNAL OF HEPATOLOGY (2016)
Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases
Yanping Xu
JOURNAL OF MEDICINAL CHEMISTRY (2016)
THE LIVER MEETING 2016-AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES, 67TH ANNUAL MEETING ( NOVEMBER 11-15, 2016-BOSTON, MASSACHUSETTS, USA)
K. Kuennemann
DRUGS OF TODAY (2016)
Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches
Meimei Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor
Xing Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia
Michael J. Genin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling
Sabrina Cipriani et al.
PLOS ONE (2015)
Nuclear receptor full-length architectures: confronting myth and illusion with high resolution
Fraydoon Rastinejad et al.
TRENDS IN BIOCHEMICAL SCIENCES (2015)
Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: Insights into the antagonism of the hypolipidemic agent Z-guggulsterone
Liping Yang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor
Donna D. Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Christina Lamers et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates
Yuichiro Amano et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice
TinaMarie Lieu et al.
GASTROENTEROLOGY (2014)
Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism
X. Hu et al.
JOURNAL OF INTERNAL MEDICINE (2014)
Exploitation of Cholane Scaffold for the Discovery of Potent and Selective Farnesoid X Receptor (FXR) and G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1) Ligands
Carmen Festa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Genome-Wide Binding and Transcriptome Analysis of Human Farnesoid X Receptor in Primary Human Hepatocytes
Le Zhan et al.
PLOS ONE (2014)
Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
Marije Boesjes et al.
PLOS ONE (2014)
Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
Sama I. Sayin et al.
CELL METABOLISM (2013)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Bile Acid Metabolism and Signaling
John Y. L. Chiang
COMPREHENSIVE PHYSIOLOGY (2013)
Unbinding Pathways of GW4064 from Human Farnesoid X Receptor As Revealed by Molecular Dynamics Simulations
Weihua Li et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists
Huang Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis
Barbara Renga et al.
PLOS ONE (2012)
Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications
Jongsook Kim Kemper
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
Dual Farnesoid X Receptor/TGR5 Agonist INT-767 Reduces Liver Injury in the Mdr2-/- (Abcb4-/-) Mouse Cholangiopathy Model by Promoting Biliary HCO3- Output
Anna Baghdasaryan et al.
HEPATOLOGY (2011)
Tuberatolides, Potent FXR Antagonists from the Korean Marine Tunicate Botryllus tuberatus
Hyukjae Choi et al.
JOURNAL OF NATURAL PRODUCTS (2011)
Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro
Deanna L. Howarth et al.
AQUATIC TOXICOLOGY (2010)
Genome-Wide Tissue-Specific Farnesoid X Receptor Binding in Mouse Liver and Intestine
Ann M. Thomas et al.
HEPATOLOGY (2010)
Target Profile Prediction: Cross-Activation of Peroxisome Proliferator-Activated Receptor (PPAR) and Farnesoid X Receptor (FXR)
Ramona Steri et al.
MOLECULAR INFORMATICS (2010)
Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
Giovanni Rizzo et al.
MOLECULAR PHARMACOLOGY (2010)
Low Retinol Levels Differentially Modulate Bile Salt-Induced Expression of Human and Mouse Hepatic Bile Salt Transporters
Martijn O. Hoeke et al.
HEPATOLOGY (2009)
Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)
Brenton Flatt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064
Adwoa Akwabi-Ameyaw et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR.
Caroline Scholtes et al.
JOURNAL OF HEPATOLOGY (2008)
Novel potent and selective bile acid derivatives as TGR5 agonists: Biological screening, structure-activity relationships, and molecular modeling studies
Hiroyuki Sato et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation
Stephen M. Soisson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Analysis of nuclear receptor pseudogenes in vertebrates: How the silent tell their stories
Zhengdong D. Zhang et al.
MOLECULAR BIOLOGY AND EVOLUTION (2008)
FXR, a multipurpose nuclear receptor
Florence Y. Lee et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Structure of the heterodimeric ecdysone receptor DNA-binding complex
S Devarakonda et al.
EMBO JOURNAL (2003)
Structural basis for bile acid binding and activation of the nuclear receptor FXR
LZ Mi et al.
MOLECULAR CELL (2003)
A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR
M Downes et al.
MOLECULAR CELL (2003)
Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump
J Cui et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation
YQ Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A natural product that lowers cholesterol as an antagonist ligand for FXR
NL Urizar et al.
SCIENCE (2002)
Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor
M Ananthanarayanan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
B Goodwin et al.
MOLECULAR CELL (2000)
Farnesoid X receptor responds to bile acids and represses cholesterol 7α-hydroxylase gene (CYP7A1) transcription
JYL Chiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor
BA Laffitte et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
